NF-kappa-B inhibitor epsilon (NFKBIE)

NF-kappa-B inhibitor epsilon (NFKBIE) is a cytoplasmic protein that functions as an inhibitor of the NF-kappa-B transcription factor complex. By binding to NF-kappa-B dimers—including p50-p65 (RELA) and p50-c-Rel complexes—it retains them in the cytoplasm, preventing their translocation to the nucleus and subsequent activation of gene transcription critical for immune responses, inflammation, and cell survival. Phosphorylation of NFKBIE targets it for degradation via the ubiquitin-proteasome pathway, thus permitting NF-kappa-B activation in response to various stimuli. NFKBIE is not primarily considered a classic druggable target like a receptor or enzyme, but its regulatory role in immune and inflammatory pathways associates it with disease pathology and therapeutic interest. No approved drugs directly target NFKBIE as of the information in the search results; modulatory effect has been reported regarding the uptake of methotrexate via SLC19A1 expression in the context of rheumatoid arthritis. There are no evidence-based, specific biomarkers or drugs for NFKBIE listed; however, it plays an indirect role in modulation of therapeutic response and disease biology in several immune-related and malignant conditions.

Other names

IKBEIkB-epsilonIkappaBepsilonI-kappa-B-epsilonNF-kappa-BIEIkB-Enuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor epsilon

Drugs could modulate activity by influencing expression/degradation of NFKBIE, thereby affecting NF-kappa-B pathway activation.